Of note, a mutation in ERBB2 interacting protein, also recognized by CD4+ T cells, exhibiting a TH1 profile, has been shown effective for mediating tumor regression in a patient with metastatic cholangiocarcinoma treated by adoptive cell transfer (17). This evidence concerns the gene ERBB2 and neoplasm.